The clinical relevance was suggested by demonstrating reduced levels of biotinidase in aggressive thyroid cancer patients’ sera as compared to the non-aggressive and benign patients’ sera by western blotting [7]. The gene discussed is BTD; the disease is thyroid gland carcinoma.